Show simple item record

A Bayesian analysis of small n sequential multiple assignment randomized trials (snSMARTs)

dc.contributor.authorWei, Boxian
dc.contributor.authorBraun, Thomas M.
dc.contributor.authorTamura, Roy N.
dc.contributor.authorKidwell, Kelley M.
dc.date.accessioned2018-11-20T15:31:19Z
dc.date.available2020-01-06T16:40:58Zen
dc.date.issued2018-11-20
dc.identifier.citationWei, Boxian; Braun, Thomas M.; Tamura, Roy N.; Kidwell, Kelley M. (2018). "A Bayesian analysis of small n sequential multiple assignment randomized trials (snSMARTs)." Statistics in Medicine 37(26): 3723-3732.
dc.identifier.issn0277-6715
dc.identifier.issn1097-0258
dc.identifier.urihttps://hdl.handle.net/2027.42/146269
dc.publisherWiley Periodicals, Inc.
dc.publisherSIAM
dc.subject.othermean‐square error
dc.subject.otherbias
dc.subject.otherclinical trial
dc.subject.otherjoint model
dc.subject.otherrare disease
dc.titleA Bayesian analysis of small n sequential multiple assignment randomized trials (snSMARTs)
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelStatistics and Numeric Data
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelScience
dc.subject.hlbtoplevelSocial Sciences
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146269/1/sim7900.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146269/2/sim7900_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146269/3/A_Bayesian_Analysis_of_snSMART_Revision_Supplimentary.pdf
dc.identifier.doi10.1002/sim.7900
dc.identifier.sourceStatistics in Medicine
dc.identifier.citedreferenceMurphy SA. Optimal dynamic treatment regimes. J R Stat Soc Stat Methodol Ser B. 2003; 65 ( 2 ): 331 ‐ 355.
dc.identifier.citedreferenceNason M, Follmann D. Design and analysis of crossover trials for absorbing binary endpoints. Biometrics. 2010; 66 ( 3 ): 958 ‐ 965.
dc.identifier.citedreferenceThall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two‐stage treatment strategies based on sequential failure times subject to interval censoring. Statist Med. 2007; 26 ( 26 ): 4687 ‐ 4702.
dc.identifier.citedreferenceThall PF. Smart design, conduct, and analysis in oncology. In: Kosorok MR, Moodie EEM, Thall PF, eds. Adaptive Treatment Strategies in Practice: Planning Trials and Analyzing Data for Personalized Medicine. Philadelphia, PA: SIAM; 2016: 41 ‐ 54. ASA‐SIAM Statistics and Applied Probablity Series.
dc.identifier.citedreferenceZeger SL, Liang K‐Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42: 121 ‐ 130.
dc.identifier.citedreferenceGupta S, Faughnan ME, Tomlinson GA, Bayoumi AM. A framework for applying unfamiliar trial designs in studies of rare diseases. J Clin Epidemiol. 2011; 64 ( 10 ): 1085 ‐ 1094.
dc.identifier.citedreferenceEvans SR. Clinical trial structures. J Exp Stroke Transl Med. 2010; 3: 8 ‐ 18.
dc.identifier.citedreferenceMakubate B, Senn S. Planning and analysis of cross‐over trials in infertility. Statist Med. 2010; 29 ( 30 ): 3203 ‐ 3210.
dc.identifier.citedreferenceHonkanen VEA, Siegel AF, Szalai JP, Berger V, Feldman BM, Siegel JN. A three‐stage clinical trial design for rare disorders. Statist Med. 2001; 20 ( 20 ): 3009 ‐ 3021.
dc.identifier.citedreferenceTamura RN, Krischer JP, Pagnoux C, et al. A small n sequential multiple assignment randomized trial design for use in rare disease research. Contemp Clin Trials. 2016; 46: 48 ‐ 51.
dc.identifier.citedreferenceLavori PW, Dawson R. A design for testing clinical strategies: biased adaptive within‐subject randomization. J R Stat Soc Ser A. 2000; 163: 29 ‐ 38.
dc.identifier.citedreferenceMurphy SA. An experimental design for the development of adaptive treatment strategies. Statist Med. 2005; 24 ( 10 ): 1455 ‐ 1481.
dc.identifier.citedreferenceDawson R, Lavori PW. Efficient design and inference for multistage randomized trials of individualized treatment policies. Biostatistics. 2011; 13: 142 ‐ 152.
dc.identifier.citedreferenceRobins J. A new approach to causal inference in mortality studies with a sustained exposure period ‐ application to control of the healthy worker survivor effect. Math Model. 1986; 7 ( 9‐12 ): 1393 ‐ 1512.
dc.identifier.citedreferenceHalekoh U, Højsgaard S, Yan J. The R package geepack for generalized estimating equations. J Stat Softw. 2006; 15 ( 2 ): 1 ‐ 11.
dc.identifier.citedreferenceHanley JA, Negassa A, Edwardes MD. GEE analysis of negatively correlated binary responses: a caution. Statist Med. 2000; 19 ( 5 ): 715 ‐ 722.
dc.identifier.citedreferenceWilliamson T, Eliasziw M, Fick GH. Log‐binomial models: exploring failed convergence. Emerg Themes Epidemiol. 2013; 10: 1 ‐ 10.
dc.identifier.citedreferencePan W, Connett JE. Selecting the working correlation structure in generalized estimating equations with application to the lung health study. Stat Sin. 2002; 12 ( 2 ): 475 ‐ 490.
dc.identifier.citedreference107th Congress. Rare diseases act of 2002. Public Law 107–280. 2002.
dc.identifier.citedreferenceGriggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Gen Metab. 2009; 96: 20 ‐ 26.
dc.identifier.citedreferenceLevin KA. Study design VII. Randomised controlled trials. Evid Based Dent. 2007; 8: 22 ‐ 23.
dc.identifier.citedreferenceBell SA, Smith CT. A comparison of interventional clinical trials in rare versus non‐rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis. 2014; 9: 1 ‐ 11.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.